Pharmaceutical Logistics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Cold Chain Logistics, Non-Cold Chain Logistics), By Component (Storage, Transportation, Monitoring components), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 94.88 Billion
CAGR (2026-2031)	7.15%
Fastest Growing Segment	Cold Chain Logistics
Largest Market	North America
Market Size (2031)	USD 143.59 Billion

Market Overview

The Global Pharmaceutical Logistics Market will grow from USD 94.88 Billion in 2025 to USD 143.59 Billion by 2031 at a 7.15% CAGR. The Global Pharmaceutical Logistics Market encompasses the specialized management of the procurement, warehousing, and transportation of medical products, ensuring their integrity and efficacy from the manufacturer to the end-user. The primary drivers supporting the market's growth include the rising global demand for temperature-sensitive biologics and vaccines, which necessitates precise cold chain management, alongside stringent Good Distribution Practice regulations that mandate enhanced supply chain security and traceability.

According to the Healthcare Distribution Alliance, in 2024, sales through U.S. pharmaceutical distributors reached $862 billion, marking a 10.4 percent increase from the previous year, which illustrates the escalating volume pressures placed on these logistics networks. However, a significant challenge impeding broader market expansion is the complexity of regulatory fragmentation across different international jurisdictions, which creates compliance bottlenecks and increases operational costs for cross-border shipments.

Key Market Drivers

The Increasing Demand for Temperature-Sensitive Biologics and Specialty Medicines is fundamentally reshaping the market, compelling logistics providers to upgrade their handling capabilities for high-value, unstable compounds. Unlike traditional small-molecule drugs, these advanced therapies—including monoclonal antibodies and cell and gene treatments—require strict temperature adherence throughout the supply chain to prevent spoilage. This structural shift has triggered a measurable surge in volume for specialized cold-chain air freight services as manufacturers prioritize integrity over cost. For instance, according to IAG Cargo, March 2025, in the 'IAG Cargo reports surges in global pharmaceutical shipments' press release, the company reported a 22 percent year-on-year increase in tonnage for its Constant Climate product in 2024, directly reflecting the pharmaceutical industry's intensifying need for precise temperature-controlled transportation solutions.

Concurrently, the Expansion of Global Cold Chain Infrastructure and Cryogenic Logistics has become a critical priority as manufacturers increasingly outsource these complex operations to specialized Third-Party Logistics (3PL) providers. To accommodate the stringent storage requirements of modern medical products, major logistics integrators are aggressively scaling their global footprint with Good Distribution Practice (GDP) compliant facilities. According to UPS, September 2024, in the 'UPS Bolsters Healthcare Logistics Capabilities' announcement, the firm confirmed it had expanded its dedicated healthcare network to include 17 million square feet of cGMP and GDP-compliant distribution space globally. This infrastructural growth is essential to manage the broader logistics environment, which is witnessing heightened activity; according to the International Air Transport Association, January 2025, in the '2024 Passenger and Cargo Market Data' report, global air cargo demand increased by 11.3 percent in 2024, underscoring the robust momentum in cross-border trade that underpins the modern pharmaceutical supply chain.

Download Free Sample Report

Key Market Challenges

The complexity of regulatory fragmentation across different international jurisdictions stands as a formidable barrier to the expansion of the Global Pharmaceutical Logistics Market. As logistics providers navigate a labyrinth of divergent national standards regarding Good Distribution Practice (GDP), serialization, and import-export protocols, they face compounded administrative burdens that erode operational efficiency. This fragmentation forces companies to maintain disparate compliance systems and dedicate substantial resources to varying documentation requirements, which directly increases the cost of cross-border trade and creates severe bottlenecks at customs entry points.

These regulatory hurdles translate into tangible operational friction that stifles the fluidity of global supply chains. According to the Healthcare Distribution Alliance, in 2025, wholesalers reported that approximately 2 percent of all serialized pharmaceutical products received still contained data discrepancies due to complex traceability requirements, with the resolution of these exceptions often taking weeks to complete. Such compliance-driven delays not only disrupt inventory management but also compel logistics networks to hold higher safety stocks, thereby inflating working capital requirements and hampering the market’s overall growth potential.

Key Market Trends

Warehouse Automation and Robotic Process Integration is becoming a pivotal strategy for logistics providers aiming to mitigate labor shortages and enhance operational precision within the pharmaceutical supply chain. Companies are increasingly deploying autonomous mobile robots (AMRs) and automated storage systems to handle the complex picking requirements of medical kits and clinical trial supplies, thereby reducing human error and increasing throughput. This shift towards technology-driven efficiency is exemplified by major industry players scaling their automated capabilities; for instance, according to DHL Group, July 2025, in the 'DHL to deploy 1,000+ additional robots across UK Operations' press release, the company announced a £550 million investment to expand its automated infrastructure and deploy over 1,000 new robots to support the growing life sciences sector.

The Adoption of Reusable Temperature-Controlled Packaging is simultaneously gaining traction as the industry seeks to align cold chain operations with aggressive corporate sustainability goals. Unlike traditional single-use passive systems, these active reusable containers offer superior temperature stability for high-value shipments while significantly lowering Scope 3 emissions through circular logistics networks. This transition is evidenced by the rising utilization rates of active containers; according to Envirotainer, April 2025, in the 'Sustainability Report 2024', the company recorded an 8.9 percent year-on-year growth in shipments in 2024, directly attributed to the pharmaceutical sector's accelerating shift toward sustainable, circular packaging solutions to minimize waste and carbon impact.

Segmental Insights

The Cold Chain Logistics segment is identified as the fastest-growing category within the Global Pharmaceutical Logistics Market. This expansion is primarily driven by the increasing global demand for temperature-sensitive products, such as biologics and vaccines, which necessitate strict thermal stability to preserve efficacy. Furthermore, regulatory bodies including the US Food and Drug Administration and the European Medicines Agency have enforced stringent Good Distribution Practice guidelines. These rigorous standards mandate precise environmental monitoring throughout the supply chain, compelling pharmaceutical companies to utilize specialized logistics services to ensure compliance and product integrity.

Regional Insights

North America maintains a leading position in the global pharmaceutical logistics market, driven primarily by the high concentration of key pharmaceutical manufacturers and significant healthcare expenditure. The region benefits from established infrastructure that supports the secure distribution of temperature-sensitive products, including biologics and vaccines. Additionally, rigorous compliance standards enforced by the U.S. Food and Drug Administration (FDA) necessitate reliable and strictly monitored supply chain solutions, which encourages market development. The high volume of clinical trials and consistent demand for prescription medications further solidify the region's control over the sector.

Recent Developments

• In April 2025, DHL Supply Chain unveiled a new Pharma Hub in Singapore, marking a €10 million investment dedicated to strengthening its life sciences logistics capabilities in the Asia Pacific region. This state-of-the-art facility was developed to address the rising industry demand for resilient and efficient cold chain solutions, driven by advancements in personalized medical treatments. The hub served as a critical node in the company's regional network, ensuring the secure storage and rapid distribution of sensitive pharmaceutical products while supporting the broader strategic goal of enhancing healthcare infrastructure across key global markets.
• In December 2024, Kuehne+Nagel inaugurated a specialized temperature-controlled cross-dock facility in Budapest, Hungary, specifically designed to enhance its healthcare logistics services across Europe. This new 2,000-square-meter hub was established to manage less-than-truckload shipments, effectively complementing the company's existing operations in Luxembourg. Engineered to maintain strict temperature zones between 2-8°C and 15-25°C, the facility ensured full compliance with Good Distribution Practice standards. The launch was a strategic move to optimize supply chain routings, thereby reducing transit times for pharmaceutical goods destined for Hungary and surrounding Central and Eastern European nations.
• In September 2024, UPS entered into a strategic agreement to acquire Frigo-Trans and its sister entity BPL, aiming to significantly expand its healthcare logistics footprint throughout Europe. This acquisition provided the company with access to an extensive network of temperature-controlled warehousing that supports ranges from cryopreservation to ambient storage, along with specialized cold chain transportation solutions. The initiative was driven by the increasing demand for reliable, integrated logistics chains in the pharmaceutical industry, allowing the organization to offer more robust, end-to-end delivery services for time-sensitive and temperature-critical medical shipments.
• In February 2024, Maersk announced the development of a large-scale cold chain facility at the Port of Rotterdam to support the specific storage needs of the pharmaceutical and fresh produce sectors. Situated adjacent to the Maasvlakte II terminal, this new center was designed to provide value-added services such as quality control, repackaging, and customs clearance while utilizing renewable energy sources. The project aimed to mitigate warehouse capacity shortages in Europe and offer healthcare companies a more integrated supply chain solution, enabling faster distribution of temperature-sensitive medical products to their final markets.

Key Market Players

• DHL Life Sciences
• UPS Healthcare
• FedEx
• Kuehne+Nagel
• Deutsche Post DHL
• DB Schenker
• Ceva Logistics
• Agility Logistics
• Marken
• AmerisourceBergen

By Type	By Component	By Region
Cold Chain Logistics Non-Cold Chain Logistics	Storage Transportation Monitoring components	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pharmaceutical Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pharmaceutical Logistics Market, By Type:

• Cold Chain Logistics
• Non-Cold Chain Logistics

• Pharmaceutical Logistics Market, By Component:

• Storage
• Transportation
• Monitoring components

• Pharmaceutical Logistics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE